Agios Pharmaceuticals, Inc.AGIONASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank44
3Y CAGR-45.0%
5Y CAGR-26.8%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-45.0%/yr
Quarterly compound
5Y CAGR
-26.8%/yr
Recent deceleration
Percentile
P44
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 1.45% |
| Q3 2025 | -4.28% |
| Q2 2025 | 24.66% |
| Q1 2025 | -12.16% |
| Q4 2024 | 14.29% |
| Q3 2024 | -4.42% |
| Q2 2024 | 12.69% |
| Q1 2024 | -11.58% |
| Q4 2023 | -7.03% |
| Q3 2023 | 21.99% |
| Q2 2023 | 2.41% |
| Q1 2023 | -4.34% |
| Q4 2022 | 8.73% |
| Q3 2022 | -12.80% |
| Q2 2022 | 6.78% |
| Q1 2022 | -4.86% |
| Q4 2021 | 15.06% |
| Q3 2021 | 3.58% |
| Q2 2021 | 8.10% |
| Q1 2021 | -42.36% |
| Q4 2020 | 6.91% |
| Q3 2020 | -1.50% |
| Q2 2020 | -0.37% |
| Q1 2020 | -14.11% |
| Q4 2019 | 4.50% |
| Q3 2019 | -5.32% |
| Q2 2019 | 12.35% |
| Q1 2019 | 1.89% |
| Q4 2018 | 13.62% |
| Q3 2018 | -4.81% |
| Q2 2018 | 10.87% |
| Q1 2018 | 1.31% |
| Q4 2017 | 5.90% |
| Q3 2017 | -8.64% |
| Q2 2017 | 27.23% |
| Q1 2017 | -3.01% |
| Q4 2016 | 6.65% |
| Q3 2016 | 19.37% |
| Q2 2016 | 15.36% |
| Q1 2016 | 19.24% |